Basal insulin glargine vs prandial insulin lispro in type 2 diabetes - Authors' reply

The Lancet

Volumn 372, Issue 9636, 2008, Pages 372-

  Linn, Thomas ^a   Landgraf, W ^b   Bretzel, Reinhard G ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN GLARGINE; INSULIN LISPRO;

BLOOD GLUCOSE MONITORING; BODY WEIGHT; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG FORMULATION; DRUG POTENTIATION; HUMAN; HYPOGLYCEMIA; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 48349132189     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61154-X     Document Type: Letter

References (4)

1. McMahon G., and Dluhy R. Intention to treat-initiating insulin and the 4-T Study. N Engl J Med 357 (2007) 1759-1761
2. Holman R., Thorne K., Farmer A., et al. Addition of biphasic prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357 (2007) 1716-1730
3. Raccah D., Bretzel R., Owens D., and Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough-what next?. Diabetes Metab Res Rev 23 (2007) 257-264
4. Kudva Y., and Montori V. Patient-centred treatments for type 2 diabetes. Lancet 371 (2008) 1047-1048